Cost-effectiveness of a primary care intervention to treat obesity

International Journal of Obesity

Volumn 37, Issue , 2013, Pages S31-S37

  Tsai, A G ^a   Wadden, T A ^b,c   Volger, S ^b   Sarwer, D B ^b   Vetter, M ^b   Kumanyika, S ^b   Berkowitz, R I ^d   Diewald, L K ^b   Perez, J ^b   Lavenberg, J ^b   Panigrahi, E R ^b   Glick, H A ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HAVERFORD COLLEGE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cost effectiveness; Costs; Primary care; Reducing diet

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAL; MEDICAL ASSISTANT; OBESITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; WEIGHT REDUCTION;

COST-BENEFIT ANALYSIS; DIET, REDUCING; DIRECTIVE COUNSELING; FEMALE; HUMANS; MALE; MEDICAID; MEDICARE; MIDDLE AGED; OBESITY; PENNSYLVANIA; PRIMARY HEALTH CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK REDUCTION BEHAVIOR; TIME FACTORS; UNITED STATES; WEIGHT LOSS;

EID: 84882434748     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.94     Document Type: Article

References (51)

1. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff 2009; 28: 822-831.
2. Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ. Indirect costs of obesity: a review of the current literature. Obes Rev 2008; 9: 489-500.
3. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 2011; 155: 434-447.
4. Rao G, Burke LE, Spring BJ, Ewing LJ, Turk M, Lichtenstein AH et al. New and emerging weight management strategies for busy ambulatory settings: a scientific statement from the American Heart Association endorsed by the Society of Behavioral Medicine. Circulation 2011; 124: 1182-1203.
5. Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med 2009; 24: 1073-1079.
6. Centers for Medicaid and Medicare Services. Decision memo for intensive behavioral therapy for obesity (CAG-00423N). Available at: http://www.cms.gov/medicare-coverage-database/details/nca-dedsion-memo.aspx?NCAId=253&ver=4&NcaName=lntensive+Behavioral+Therapy+for+Obesity&DoclD=CAG-00423N& from2=search.asp&bc=gAAAAAgAIAAA&. Accessed on 14 December 2012.
7. Buchwald H, Avidor Y, Braunwald E, Jenson MD, Poires W, Fahrbach K et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.
8. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
9. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res 2004; 12(Suppl): 151S-162S.
10. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26: 2518-2523.
11. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143: 251-264.
12. Herman WH, Hoerger TJ, Brandie M, Hicks K, Sorensen S, Zhang P et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 323-332.
13. Wadden TA, Volger S, Sarwer DB, Vetter M, Tsai A, Berkowitz R et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011; 365: 1969-1979.
14. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011; 365: 1959-1968.
16. Bennett GG, Warner ET, Glasgow RE, Askew S, Goldman J, Ritzwoller D et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. Arch Intern Med 2012; 172: 565.
17. Yeh HC, Clark JM, Emmons KE, Moore RH, Bennett GG, Warner ET et al. Independent but coordinated trials: insights from the practice-based Opportunities for Weight Reduction Trials Collaborative Research Group. Clin Trials 2010; 7: 322-332.
18. United States Department of Veterans Affairs. Drug Pharmaceutial Prices: Federal Supply Schedule, http://www.pbm.va.gov/drugpharmaceuticalprices.asp. Accessed on 1 May 2013.
19. Herman WH, Brandie M, Zhang P, Williamson DF, Matulik MJ, Ratner RE et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003; 26: 36-47.
20. United States Department of Labor Bureau of Labor Statistics. Consumer Price Index, http://www.bls.gov/cpi/. Accessed on 1 November 2012.
21. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decls Making 2006; 26: 410-420.
22. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88: 1550-1559.
23. Spielman AB, Kanders B, Kienholz M, Blackburn GL. The cost of losing: an analysis of commercial weight-loss programs in a metropolitan area. J Am Coll Nutr 1992; 11:36-41.
24. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. 1st edn. (Oxford University Press: Oxford, UK, 2007).
25. Lin DY. Linear regression analysis of censored medical costs. Biostatlstlcs 2000; 1: 35-47.
26. Lin DY. Regression analysis of incomplete medical cost data. Stat Med 2003; 22: 1181-1200.
27. Diabetes Prevention Program Research G. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012; 35: 723-730.
28. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
29. Krukowski RA, Tilford JM, Harvey-Berino J, West DS. Comparing behavioral weight loss modalities: incremental cost-effectiveness of an internet-based versus an in-person condition. Obesity 2011; 19: 1629-1635.
30. Roux L, Kuntz KM, Donaldson C, Goldie SJ. Economic evaluation of weight loss interventions in overweight and obese women. Obesity 2006; 14: 1093-1106.
31. Gustafson A, Khavjou O, Stearns SC, Keyserling TC, Gizlice Z, Lindsley S et al. Cost-effectiveness of a behavioral weight loss intervention for low-income women: the Weight-Wise Program. Prev Med 2009; 49: 390-395.
32. Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler JL, Oneida B et al. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care 2004; 27: 1570-1576.
33. Wolf AM, Siadaty M, Yaeger B, Conaway MR, Crowther JQ, Nadler JL et al. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). J Am Diet Assoc 2007; 107: 1365-1373.
34. John LK, Loewenstein G, Troxel AB, Norton L, Fassbender JE, Volpp KG. Financial incentives for extended weight loss: a randomized, controlled trial. J Gen Intern Med 2011; 26: 621-626.
35. Anderson JW, Jhaveri MA. Reductions in medications with substantial weight loss with behavioral intervention. Curr Clin Pharmacol 2010; 5: 232-238.
36. Collins RW, Anderson JW. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med 1995; 24: 369-374.
37. Redmon JB, Bertoni AG, Connelly S, Feeney PA, Glasser SP, Glick H et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010; 33: 1153-1158.
38. Avenell A, Broom J, Brown TJ, Aucott L, Stearns SC, Smith WCS et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: 1-182.
39. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health 2007; 52: 372-382.
40. McConnon A, Kirk SF, Cockroft JE, Harvey EL, Greenwood DC, Thomas JD et al. The Internet for weight control in an obese sample: results of a randomised controlled trial. BMC Health Serv Res 2007; 7: 206.
41. Tsai AG, Glick HA, Shera D, Stern L, Samaha FF. Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity. Obes Res 2005; 13: 1834-1840.
42. Olsen J, Willaing I, Ladelund S, Jorgensen T, Gundgaard J, Sorensen J. Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease. Int J Technol Assess Health Care 2005; 21: 194-202.
43. van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling longterm health gains through prevention of obesity-related chronic diseases. Value Health 2008; 11: 1033-1040.
44. Zhang P, Lawlor M, Davis C, Dotson K, Rushing J, Espeland M et al. Costs associated with delivering a structured lifestyle intervention and diabetes education program in overweight and obese adults with type 2 diabetes: year 4 results from the Action for Health in Diabetes (Look AHEAD) Study. Diabetes Care 2011; 60: A68.
45. Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575.
46. Baicker K, Cutler D, Song Z. Workplace wellness programs can generate savings. Health Aff 2010; 29: 304-311.
47. Russell LB. Preventing chronic disease: an important investment, but don't count on cost savings. Health Aff 2009; 28: 42-45.
48. O'Grady MJ, Capretta JC. Assessing the Economics of Obesity and Obesity Interventions. Campaign to End Obesity: Washington, DC, 2012.
49. National Institute for Clinical Excellence. NICE issues guidance on Orlistat for obesity. 2001; http://www.nice.org.uk/guidance/index.jsp?action=article&o=32161. Accessed on 20 April 2012.
50. Heshka S, Anderson JW, Atkinson RL, Greenway FL, Hill JO, Phinney SD et al. Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA 2003; 289: 1792-1798.
51. Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, Stoll J et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet 2011; 378: 1485-1492.